NATIONAL INCUBATOR SHIFTS INTO GEAR, ANNOUNCING VACCINE AND INFECTIOUS DISEASE INNOVATION COHORT Six Australian infectious disease innovations receive $10.48 million to accelerate commercialisation potential
With
Jenny Herz,
Co-Founder and Executive Director
Biointelect
Danielle Shand,
General Manager
Biointelect Venturer
SEGMENT
Filmed in Sydney | September 2026
Biointelect Venturer is Australia’s national incubator for infectious disease innovation, helping promising Australian scientific innovators accelerate their path from discovery to impact. Funded by the Australian Government’s Medical Research Future Fund (MRFF) through the 2024 BioMedTech Incubator grant opportunity, Biointelect Venturer combines catalytic non-dilutive funding with commercialisation expertise, strategic guidance, networks and tailored support to progress early-stage innovations towards commercial and investment readiness. Managed and operated by Biointelect, the incubator builds on Biointelect’s deep expertise and success in supporting early-stage biotech and medtech commercialisation.
Biointelect Venturer has announced six Australian infectious disease innovations will share $10.48 million in the incubator’s first funding round giving the successful research teams the ability to advance their early-stage breakthroughs to commercial and investment readiness.
– AdaptiVax Pty Ltd
– Ebivanta Therapeutics Pty Ltd
– ENA Respiratory Pty Ltd
– Proboxis Biotechnology Pty Ltd
– Saccharide Therapeutics Pty Ltd
– SAMMvax Pty Ltd
The recipients address significant local and global unmet health needs in infectious disease and include three vaccine offerings, a unique nasal antiviral technology and two vaccine platform technologies.
The projects will now enter the Biointelect Venturer incubation program for up to two years and receive non-dilutive funding, tailored commercialisation support, expert mentoring and access to national and international networks to help progress their technologies to secure commercial interest and funding.
Biointelect Venturer was established through a $32.9 million Medical Research Future Fund (MRFF) grant from the Australian Government’s MRFF Medical Research Commercialisation initiative. It will support two national cohort intakes, this being the first, and a dedicated top-up round for high-potential projects as part of the program.
Biointelect Venturer is helping to build local capability in translational research and commercialisation and supporting the creation and growth of Australian biotech companies developing health technologies across the infectious disease sector. Ultimately the ambition is to strengthen Australia’s position as a global infectious disease innovation hub.
Source: Adapted from Biointelect media release (August 2026)
-
25 years of non-indexation of nuclear medicine impeding access & affordability
The President of the Australasian Association of Nuclear Medicine Specialists (AANMS), Associate Professor Sze Ting Lee spoke with Australian Health Journal about the following:
Usual levels of nuclear medicine services in Australia each year
Current levels of nuclear medicine services in Australia
How changing demographics in people moving to regional areas has impacted access to nuclear medicine services
The nuclear medicine workforce including trainees
The key recommendations from the pre-budget submissionIn the lead up to the Australian Federal Budget in May 2023, Australian Health Journal reached out to peak health industry bodies to hear about their priorities, either noted in pre-budget submissions lodged with Federal Government in January 2023 or in recent forums such as the Strengthening Medicare Taskforce.
-
Allied Health Leader shares career insights
Mirella Vagnarelli is a distinguished healthcare leader with proven expertise across South Australia and the United Kingdom, where she has successfully led large, multidisciplinary teams. Holding a Master of Business Administration (Health) from Flinders University, she earned Fellowship status with the Australasian College of Health Service Management in 2022. In 2023, Mirella was honoured as a scholarship recipient for the prestigious ‘Women in Leadership’ Program at the Monash Centre for Health Research and Implementation.
-
Landmark Australian-led study revises thresholds to diagnose and treat anaemia
In 2014, WEHI researchers began a study at the request of the World Health Organization (WHO), to formally review its global anaemia guidelines that were last updated in 1968.
Study lead and Acting WEHI Deputy Director, Professor Sant-Rayn Pasricha, speaking to Australian Health Journal said while anaemia can be diagnosed by measuring the amount of haemoglobin in the blood, there is currently no consensus on the thresholds that should be used to define the condition.
